ofranergene obadenovec

June 9, 2020June 9, 2020

More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows

News

VBL Therapeutic’s investigational therapy VB-111 (ofranergene obadenovec) continues to show promising response rates in women with platinum-resistant ovarian cancer, with more than half of patients enrolled in a Phase 3 ... Read more

February 5, 2018

First Patient Dosed in Phase 3 Trial Testing VB-111 in Platinum-resistant Ovarian Cancer

News

VBL Therapeutics has successfully administered the initial dose to the first patient in its Phase 3 trial investigating the effects of VB-111 (ofranergene obadenovec) in platinum-resistant ovarian cancer. The pivotal OVAL ... Read more